Anzeige
Mehr »
Login
Donnerstag, 26.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
614 Leser
Artikel bewerten:
(1)

First in the World - an ECG-necklace as a Medical Device Revolutionises the Self-monitoring of the Heart Rhythm

Finanznachrichten News

HELSINKI, May 27, 2020 /PRNewswire/ -- Heart2Save and Lumoava, both from Finland, decided to combine their expertise; the result is a new generation medical device - an ECG-necklace, AiVoni ?? Lumoava. The beautiful design, combined with reliable arrhythmia analysis enables you to monitor the well-being of your heart in a stylish, unnoticeable way - at home, at work, on holiday - no matter where you are.

New products for the identification and screening of arrhythmias are being developed at high speed all over the world. The consumer experience is vital, the products must be easy and practical to use in everyday life. Stylish design and ease of use play a significant role in how the consumer embraces the product in the long run. In wellness and sports products, the design is something that is self evident, but when talking about medical devices, the AiVoni ?? Lumoava ECG-necklace is the starting point for a new era of self-monitoring.

"Heart2Save has strong roots in science, and our products are medical devices. They have thus gone through the same demanding process as devices used in hospitals, so the information they provide can be trusted. In order to catch an occasional arrhythmia or asymptomatic atrial fibrillation repeated measurements are required. The measurements are easily done with a device that you always have with you, like a piece of jewellery. A medical device, as a design product, also does not stigmatise the user as someone having a heart disease. These were the starting points for Heart2Save's and Lumoava's idea to make a necklace into a medical device", says Helena Jäntti, Emergency Doctor, CEO Heart2Save.

The research behind the ECG-necklace was first showcased at a scientific congress organised by the European Society of Cardiology (ESC) in May 2020. According to the findings, the ECG-necklace produced ECG recordings with excellent quality, from where both cardiologists and AiVoni arrhythmia detection algorithms could reliably identify arrhythmia. In self-monitoring products, accurate AI-based analyses are necessary so that the consumer doesn't have to interpret the ECG him/herself. The results received widespread international attention. Enclosed a link to the press release by ESC.

https://www.escardio.org/The-ESC/Press-Office/Press-releases/Novel-necklace-detects-abnormal-heart-rhythm

"It was easy for Lumoava to start a collaboration with Heart2Save, as we share the same values and have the right combination of expertise and knowledge. We have 75 years of experience in designing jewellery and working with silver, so it has been truly inspiring to join forces in the challenging process of designing and manufacturing this innovative medical device. How to develop a beautiful piece of jewellery, which at the same time is a life-saving medical device? We listened to our hearts and accepted the challenge, and soon these unique AiVoni ?? Lumoava necklaces will be manufactured in Kuopio", says Mikko Pessi, the proud CEO of Saurum.

About Heart2Save Ltd

Heart2Save is a Kuopio-based health tech company founded in 2015, with its core competence in identification of heart arrhythmias. The company has extensive and diverse knowledge in different branches of science, e.g. medicine, algorithms, medical device regulation, product development and usability. We have two passionate goals: to prevent strokes and to create value with our product for patients, society, and investors.

About Saurum Ltd

Saurum Ltd, founded in 1942, has a long background as a manufacturer of high-quality silver and gold jewellery. Saurum manufactures all the products of the Finnish design brand Lumoava in Kuopio, at the world's northernmost jewellery factory. Lumoava is the official partner of the Finnish Olympic Committee and has been awarded the Design from Finland and the Key Flag Symbols.

For more information, please contact:
Helena Jäntti, CEO, Heart2Save Ltd
+358-40-553-8438
helena.jantti@heart2save.com
www.heart2save.com

Mikko Pessi, CEO, Saurum Ltd
+358-40-304-0210
mikko.pessi@saurum.fi
www.saurum.fi

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/heart2save/r/first-in-the-world---an-ecg-necklace-as-a-medical-device-revolutionises-the-self-monitoring-of-the-h,c3119081

The following files are available for download:

https://mb.cision.com/Main/18483/3119081/1253030.pdf

Press release (PDF)

https://news.cision.com/heart2save/i/ecg-necklace,c2788959

ECG-necklace

© 2020 PR Newswire
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.